{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:16:10Z","timestamp":1765610170956,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Miguel Servet Program CP20\/00106"],"award-info":[{"award-number":["Miguel Servet Program CP20\/00106"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Coronavirus Disease of 2019 (COVID-19) pandemic caused by SARS-CoV-2 led the Spanish government to impose a national lockdown in an attempt to control the spread of the infection. Mobility restrictions and the requirement of a medical prescription for serological testing for COVID-19 were included among the control measures. Under this scenario, between April 15th and June 15th, 2020, we performed an observational study including 449 individuals allowed to be tested according to the governmental restrictions, i.e. fulfilling the following prescription requirements: manifestation of COVID-19-compatible symptoms, contact with a confirmed COVID-19 patient, or employment as an essential worker, including health care workers, firefighters and public safety personnel such as police. Importantly, a relevant feature of the studied cohort was that none of the participants had been hospitalized. We analyzed SARS-CoV-2 IgG seropositivity in this specific cohort, uncovering intrinsic features of great demographic interest. The overall rate of IgG seropositivity was 33.69% (95% CI: 29.27\u201338.21). This frequency was comparable among the different participant occupations. A RT-PCR positive test, contact with a household member previously tested positive and the presence of COVID-19-compatible symptoms were positively associated with IgG\u2009+\u2009results. Among these symptoms, ageusia\/anosmia was positively and independently associated with SARS-CoV-2 IgG seropositivity, while odynophagia was inversely associated. However, fever, ageusia\/anosmia and asthenia were the most frequent symptoms described by IgG\u2009+\u2009subjects. Therefore, our data illustrate how specific cohorts display particular characteristics that should be taken into account when studying population-wide SARS-CoV-2 seroprevalence and key defining symptoms of COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-021-00990-4","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T11:04:18Z","timestamp":1635937458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown"],"prefix":"10.1038","volume":"11","author":[{"given":"Patricia Torres","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Diaque","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Rubio","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Rodr\u00edguez","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Avenda\u00f1o-Ort\u00edz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Guerrero-Monjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Llamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"L\u00f3pez-Collazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Saz-Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"del Fresno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"990_CR1","doi-asserted-by":"publisher","unstructured":"Mulligan, M. J. et al. Final-submission v2.0 P a g e | 1 Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv 2020.06.30.20142570 (2020) doi:https:\/\/doi.org\/10.1101\/2020.06.30.20142570.","DOI":"10.1101\/2020.06.30.20142570"},{"key":"990_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14364","author":"AK Azkur","year":"2020","unstructured":"Azkur, A. K. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy https:\/\/doi.org\/10.1111\/all.14364 (2020).","journal-title":"Allergy"},{"key":"990_CR3","doi-asserted-by":"publisher","unstructured":"Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science (80-. ). eabb3221 (2020). https:\/\/doi.org\/10.1126\/science.abb3221.","DOI":"10.1126\/science.abb3221"},{"key":"990_CR4","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jama.2020.3204","volume":"323","author":"BE Young","year":"2020","unstructured":"Young, B. E. et al. Epidemiologic Features and Clinical Course of Patients Infected with SARS-CoV-2 in Singapore. JAMA - J. Am. Med. Assoc. 323, 1488\u20131494 (2020).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"990_CR5","doi-asserted-by":"publisher","unstructured":"Lin, L., Lu, L., Cao, W. & Li, T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 1\u201314 (2020). https:\/\/doi.org\/10.1080\/22221751.2020.1746199.","DOI":"10.1080\/22221751.2020.1746199"},{"key":"990_CR6","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Invest."},{"key":"990_CR7","doi-asserted-by":"crossref","unstructured":"Leal, F. E. et al. Clinical features and natural history of the first 2073 suspected COVID-19 cases in the Corona S\u00e3o Caetano primary care programme: a prospective cohort study. BMJ Open vol. 11 (2021).","DOI":"10.1136\/bmjopen-2020-042745"},{"key":"990_CR8","doi-asserted-by":"crossref","unstructured":"Singh, R. et al. COVID\u201019: Current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 35, (2021).","DOI":"10.1096\/fj.202002662R"},{"key":"990_CR9","doi-asserted-by":"publisher","unstructured":"Prather, K. A., Wang, C. C. & Schooley, R. T. Reducing transmission of SARS-CoV-2. Science (80-. ). eabc6197 (2020) doi:https:\/\/doi.org\/10.1126\/science.abc6197.","DOI":"10.1126\/science.abc6197"},{"key":"990_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6810","author":"T Britton","year":"2020","unstructured":"Britton, T., Ball, F. & Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science https:\/\/doi.org\/10.1126\/science.abc6810 (2020).","journal-title":"Science"},{"key":"990_CR11","doi-asserted-by":"publisher","unstructured":"Poll\u00e1n, M. et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet (London, England) (2020). https:\/\/doi.org\/10.1016\/S0140-6736(20)31483-5.","DOI":"10.1016\/S0140-6736(20)31483-5"},{"key":"990_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17318-x","volume":"11","author":"AL Garcia-basteiro","year":"2020","unstructured":"Garcia-basteiro, A. L. et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat. Commun. 11, 1\u201336 (2020).","journal-title":"Nat. Commun."},{"key":"990_CR13","doi-asserted-by":"publisher","unstructured":"Barallat, J., Fern\u00e1ndez-Rivas G, -S\u00e1nchez B, Q. & Martinez-Caceres. Seroprevalence of SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. doi:https:\/\/doi.org\/10.1101\/2020.06.24.20135673.","DOI":"10.1101\/2020.06.24.20135673"},{"key":"990_CR14","unstructured":"Espa\u00f1a. Ministerio de la Presidencia. Real Decreto 463\/2020. Bolet\u00edn Of. del Estado 67, 25390\u201325400 (2020)."},{"key":"990_CR15","doi-asserted-by":"publisher","unstructured":"Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 313\u2013319 (2020) doi:https:\/\/doi.org\/10.1016\/S0140-6736(20)31304-0.","DOI":"10.1016\/S0140-6736(20)31304-0"},{"key":"990_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12890-020-01237-0","volume":"20","author":"G Sotgiu","year":"2020","unstructured":"Sotgiu, G. et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. BMC Pulm. Med. 20, 203 (2020).","journal-title":"BMC Pulm. Med."},{"key":"990_CR17","doi-asserted-by":"crossref","unstructured":"Korth, J. et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J. Clin. Virol. 128, (2020).","DOI":"10.1016\/j.jcv.2020.104437"},{"key":"990_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30315-5","author":"SJC Pallett","year":"2020","unstructured":"Pallett, S. J. C. et al. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. Lancet. Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30315-5 (2020).","journal-title":"Lancet. Respir. Med."},{"key":"990_CR19","doi-asserted-by":"crossref","unstructured":"Stubblefield, W. B. et al. Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients \u2014 Nashville, Tennessee. Clin. Infect. Dis. (2020).","DOI":"10.1093\/cid\/ciaa936"},{"key":"990_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.067","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J. Infect. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.067 (2020).","journal-title":"J. Infect."},{"key":"990_CR21","doi-asserted-by":"publisher","unstructured":"Garralda Fern\u00e1ndez, J., Molero Vilches, I., Bermejo Rodr\u00edguez, A. & Cano Torres, I. Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain. medRxiv (2020). https:\/\/doi.org\/10.1101\/2020.07.26.20162529.","DOI":"10.1101\/2020.07.26.20162529"},{"key":"990_CR22","doi-asserted-by":"crossref","unstructured":"Fischer, B., Knabbe, C. & Vollmer, T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Eurosurveillance 25, (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001285"},{"key":"990_CR23","doi-asserted-by":"publisher","unstructured":"Newberry, J. A. et al. SARS-CoV-2 IgG Seropositivity and Acute Asymptomatic Infection Rate Among Firefighter First Responders in an Early Outbreak County in California. Prehospital Emerg. Care 1\u201310 (2021) doi:https:\/\/doi.org\/10.1080\/10903127.2021.1912227.","DOI":"10.1080\/10903127.2021.1912227"},{"key":"990_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0242124","volume":"15","author":"WA Halatoko","year":"2020","unstructured":"Halatoko, W. A. et al. Prevalence of SARS-CoV-2 among high-risk populations in Lom\u00e9 (Togo) in 2020. PLoS ONE 15, 1 (2020).","journal-title":"PLoS ONE"},{"key":"990_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/22221751.2020.1773324","volume":"9","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg. Microb. Infect. 9, 1269\u20131274 (2020).","journal-title":"Emerg. Microb. Infect."},{"key":"990_CR26","doi-asserted-by":"publisher","unstructured":"Li, L. et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion trf.15918 (2020) doi:https:\/\/doi.org\/10.1111\/trf.15918.","DOI":"10.1111\/trf.15918"},{"key":"990_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2020.04.012","volume":"52","author":"HE Randolph","year":"2020","unstructured":"Randolph, H. E. & Barreiro, L. B. Herd Immunity: Understanding COVID-19. Immunity 52, 737\u2013741 (2020).","journal-title":"Immunity"},{"key":"990_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4130","author":"FP Havers","year":"2020","unstructured":"Havers, F. P. et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4130 (2020).","journal-title":"JAMA Intern. Med."},{"key":"990_CR29","doi-asserted-by":"publisher","unstructured":"Griffin, S. Covid-19: Herd immunity is \u201cunethical and unachievable,\u201d say experts after report of 5% seroprevalence in Spain. BMJ m2728 (2020) doi:https:\/\/doi.org\/10.1136\/bmj.m2728.","DOI":"10.1136\/bmj.m2728"},{"key":"990_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa310","author":"L Guo","year":"2020","unstructured":"Guo, L. et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa310 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"990_CR31","doi-asserted-by":"publisher","unstructured":"Liu, R. et al. The comparative superiority of IgM-IgG antibody test to real-time reverse 1 transcriptase PCR detection for SARS-CoV-2 infection diagnosis 2 Corresponding authors 1 8. https:\/\/doi.org\/10.1101\/2020.03.28.20045765.","DOI":"10.1101\/2020.03.28.20045765"},{"key":"990_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"990_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: Current State of the Science. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2020.05.002 (2020).","journal-title":"Immunity"},{"key":"990_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.015","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.05.015 (2020).","journal-title":"Cell"},{"key":"990_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.023","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2020.04.023 (2020).","journal-title":"Immunity"},{"key":"990_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2598-9","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature https:\/\/doi.org\/10.1038\/s41586-020-2598-9 (2020).","journal-title":"Nature"},{"key":"990_CR37","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842\u2013844 (2020).","journal-title":"Nat. Med."},{"key":"990_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1072","author":"AR Yousaf","year":"2020","unstructured":"Yousaf, A. R. et al. A prospective cohort study in non-hospitalized household contacts with SARS-CoV-2 infection: symptom profiles and symptom change over time. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1072 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"990_CR39","doi-asserted-by":"publisher","unstructured":"Israel, A. et al. Smoking and the risk of COVID-19 in a large observational population study. https:\/\/doi.org\/10.1101\/2020.06.01.20118877.","DOI":"10.1101\/2020.06.01.20118877"},{"key":"990_CR40","doi-asserted-by":"crossref","unstructured":"Kantele, A. et al. SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors. Travel Med. Infect. Dis. 39, 101949 (2021).","DOI":"10.1016\/j.tmaid.2020.101949"},{"key":"990_CR41","unstructured":"De Santi, M., Diotallevi, A. & Brandi, G. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy. Acta Biomed. 92, e2021070 (2021)."},{"key":"990_CR42","doi-asserted-by":"publisher","unstructured":"Lynch, K. L. et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. medRxiv 2020.06.03.20121525 (2020) doi:https:\/\/doi.org\/10.1101\/2020.06.03.20121525.","DOI":"10.1101\/2020.06.03.20121525"},{"key":"990_CR43","doi-asserted-by":"crossref","unstructured":"Lombardi, A. et al. Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: A cross-sectional study. BMJ Open 11, (2021).","DOI":"10.1136\/bmjopen-2020-047216"},{"key":"990_CR44","doi-asserted-by":"crossref","unstructured":"Zejda, J. E. et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland. Int. J. Environ. Res. Public Health 18, (2021).","DOI":"10.3390\/ijerph18063188"},{"key":"990_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10238-020-00648-x","volume":"20","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou, M. et al. Organ-specific manifestations of COVID-19 infection. Clin. Exp. Med. 20, 493\u2013506 (2020).","journal-title":"Clin. Exp. Med."},{"key":"990_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00405-020-06120-6","volume":"278","author":"E Mehraeen","year":"2021","unstructured":"Mehraeen, E. et al. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur. Arch. Otorhinolaryngol. 278, 307\u2013312 (2021).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"990_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02379-z","author":"F Lapostolle","year":"2020","unstructured":"Lapostolle, F. et al. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern. Emerg. Med. https:\/\/doi.org\/10.1007\/s11739-020-02379-z (2020).","journal-title":"Intern. Emerg. Med."},{"key":"990_CR48","unstructured":"Jefatura del Estado, B. Disposici\u00f3n 3824 del BOE n\u00fam. 73 de 2020. https:\/\/www.boe.es (2020)."},{"key":"990_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/aje\/kwaa174","volume":"190","author":"CT Sempos","year":"2021","unstructured":"Sempos, C. T. & Tian, L. Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error. Am. J. Epidemiol. 190, 109\u2013115 (2021).","journal-title":"Am. J. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00990-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:53:04Z","timestamp":1670086384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00990-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00990-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"16 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.LL, F.G and C.delF. are founders, board members and shareholders of EMPIREO Diagn\u00f3stico Molecular. E.L.-C. is founder and shareholder of EMPIREO Diagn\u00f3stico Molecular. P.T.M, was and P.D.G., M.R.S., S.G-M and R.R.S. are employees of EMPIREO Diagn\u00f3stico Molecular. J.A-O and P.S-L. do not declare potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21612"}}